- Home
- AACG vs INKT Comparison
AACG vs INKT Comparison
Compare AACG & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- INKT
- Stock Information
- Founded
- AACG 1999
- INKT 2017
- Country
- AACG China
- INKT United States
- Employees
- AACG N/A
- INKT N/A
- Industry
- AACG Other Consumer Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- AACG Real Estate
- INKT Health Care
- Exchange
- AACG Nasdaq
- INKT Nasdaq
- Market Cap
- AACG 31.9M
- INKT 34.9M
- IPO Year
- AACG N/A
- INKT 2021
- Fundamental
- Price
- AACG $0.92
- INKT $1.04
- Analyst Decision
- AACG
- INKT Strong Buy
- Analyst Count
- AACG 0
- INKT 2
- Target Price
- AACG N/A
- INKT $6.50
- AVG Volume (30 Days)
- AACG 24.9K
- INKT 216.6K
- Earning Date
- AACG 11-07-2024
- INKT 11-14-2024
- Dividend Yield
- AACG N/A
- INKT N/A
- EPS Growth
- AACG N/A
- INKT N/A
- EPS
- AACG N/A
- INKT N/A
- Revenue
- AACG $35,747,843.00
- INKT N/A
- Revenue This Year
- AACG N/A
- INKT N/A
- Revenue Next Year
- AACG N/A
- INKT N/A
- P/E Ratio
- AACG N/A
- INKT N/A
- Revenue Growth
- AACG 15.80
- INKT N/A
- 52 Week Low
- AACG $0.50
- INKT $0.46
- 52 Week High
- AACG $1.65
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- AACG 52.00
- INKT 60.31
- Support Level
- AACG $0.92
- INKT $0.82
- Resistance Level
- AACG $1.04
- INKT $0.98
- Average True Range (ATR)
- AACG 0.06
- INKT 0.13
- MACD
- AACG 0.01
- INKT 0.02
- Stochastic Oscillator
- AACG 66.13
- INKT 47.37
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.